ASX Faces Rebound, Cost Shock and Trial Timing Over Long Weekend

ASX Faces Rebound, Cost Shock and Trial Timing Over Long Weekend

June 7, 2026

Sydney, June 8, 2026, 06:02 (AEST)

ASX Ltd is steady going into the holiday week, with shares ending Friday at A$47.68, up 1.53%. The market is closed Monday for the King’s Birthday, as shown on ASX’s trading calendar, which marks June 8 with no settlement. The next open session and test for the stock is set for Tuesday.

The question is pressing now as the stock tries to stabilize after its May drop. Investors face a soft local market when they come back. The S&P/ASX 200, the main Australian blue-chip index, closed down 0.70% at 8,625.10 on Friday, hit by weakness in banks and miners. ASX Ltd finished higher.

ASX trades as a company and runs Australia’s main exchange, so it stands out for investors. Shares gained 3.14% over the week ending Friday, but that hasn’t erased losses from May 26. Reuters reported ASX dropped 13.2% that day, its sharpest fall since April 2000, after new spending guidance shook some holders.

Spending is still the main focus. ASX said on May 26 that it expects total expenses in FY27 to jump 18% to 21%, and it raised its FY27 capex guidance to A$180 million-A$200 million. Capex is money spent on assets like technology systems. The company kept its FY26 expense growth outlook at 20% to 23%, including costs related to the ASIC probe and commitments plan.

Greg Smith, investment specialist at Generate KiwiSaver, told Reuters the market is “still scarred” by the failed CHESS upgrade, meaning the dropped ASX clearing and settlement overhaul. CHESS handles share records and settlement after trades. Smith said the key is execution now—“without more delays, outages or cost blowouts.” Reuters

ASX activity in May saw a pickup in trading, with average daily cash-market trades jumping 37% over the past year and daily on-market value up 15% at A$7.494 billion, according to the exchange’s monthly report. But listings slumped. Total new capital quoted dropped to A$3.5 billion from A$6.8 billion, while net new capital quoted came in at minus A$2.0 billion.

ASX brought in Anthony Attia, who worked at Euronext and Intercontinental Exchange, as its new managing director and CEO. He starts Sept. 1. Chair David Clarke pointed to Attia’s “technology-enabled transformation” experience. The move comes with more competition in the market. Cboe Australia, also regulated by ASIC, trades Australian shares too. So ASX still faces direct competition in cash equities, even though it remains a key player in market infrastructure.

Legal action against ASX keeps moving. The Federal Court rejected ASX’s request to make Digital Asset CEO Yuval Rooz appear in person for the ASIC trial connected to the failed CHESS upgrade, The Australian reported Friday. Instead, Rooz can be questioned remotely. ASIC alleges ASX misled in February 2022, saying the upgrade was still set for April 2023. The ASIC hearing is set for June 15, according to its case page.

But that rebound looks shaky heading into Tuesday if offshore sentiment sours or new legal news hits. Wall Street slid Friday after hotter U.S. jobs numbers chilled hopes for a rate cut, with the Nasdaq off 4.18%. Any global weakness is set to spill into Sydney after the holiday. For the ASX, more tech spending, another holdup, or tougher rules could keep traders worried about cash burning instead of higher trading volumes.

Focus shifts from Monday to Tuesday as investors decide how to price in Friday’s local market slide, the U.S. decline, and the June 15 ASIC trial coming up. ASX said it is in talks to reset its Accelerate Program with ASIC and the Reserve Bank of Australia by the end of June, providing another governance check for the stock ahead of FY26 results on Aug. 13.

Stock Market Today

  • Record High NHS Diagnostic Test Waiting List in England Raises Health Concerns
    June 7, 2026, 4:46 PM EDT. A record 1.92 million patients in England are waiting for NHS diagnostic tests, including CT and MRI scans, raising serious health concerns. Demand outpaces supply, with over 400,000 people waiting longer than the six-week NHS target. The waiting list has surged 83% since before the COVID-19 pandemic and may reach 2 million by 2027. Delays threaten timely cancer diagnosis and treatment for other serious conditions, according to a Magentus report. The Patients Association warns that prolonged waits can worsen health outcomes, as diagnostic tests are critical for initiating treatment. NHS capacity struggles amid rising demand from an ageing population and increased chronic illness prevalence.